论文部分内容阅读
在狗的冠脉血栓模型上，Ｐ６Ａ可以增加冠脉血流量，并改善血流动力学。纤维蛋白与ＧＰＩＩｂ／ＩＩＩａ受体结合时，ＲＧＤ是关键序列。本文测了Ｐ６Ａ，ＱＰ６Ａ与ＲＧＤＳ，ＲＧＤＶ，及ＲＧＤＦ生成的偶联化合物的效应。研究了这些偶联化合物的抗动脉血栓作用。在５μｍｏｌ／ｋｇ剂量下，ＲＧＤＳ和ＲＧＤＶ不显示抗血栓活性，而在２．５μｍｏｌ／ｋｇ剂量下，ＲＧＤＦ却能够明显减小血栓干重。此外，Ｐ６Ａ（５μ／ｍｏｌ／ｋｇ）和ＱＰ６Ａ（２．５μｍｏｌ／ｋｇ）显示明显的抗血栓活性。除Ｐ６Ａ－ＲＧＤＦ和ＱＰ６Ａ－ＲＧＤＦ以外，所有的偶联化合物都有强抗血栓作用。
P6A can increase coronary blood flow and improve hemodynamics in dog models of coronary artery thrombosis. RGD is the key sequence when fibrin binds to the GPIIb / IIIa receptor. This article measured the effect of the coupling compounds produced by P6A, QP6A and RGDS, RGDV, and RGDF. The anti-arterial thrombosis effects of these coupling compounds were studied. RGDS and RGDV did not show antithrombotic activity at a dose of 5 μmol / kg, whereas RGDF significantly reduced thrombus dry weight at a dose of 2.5 μmol / kg. In addition, P6A (5μ / mol / kg) and QP6A (2.5μmol / kg) showed significant antithrombotic activity. With the exception of P6A-RGDF and QP6A-RGDF, all the coupling compounds have a strong antithrombotic effect.